13
Participants
Start Date
May 7, 2021
Primary Completion Date
December 31, 2023
Study Completion Date
June 30, 2025
Almonertinib
Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
NOT_YET_RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Beijing Chest Hospital, Capital Medical University, Beijing
NOT_YET_RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
The Second Xiangya Hospital of Central South University, Changsha
NOT_YET_RECRUITING
Xinqiao Hospital, Army Medical University, Chongqing
RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
Fujian Provincial Hospital, Fuzhou
NOT_YET_RECRUITING
Sir Run Run Shaw Hospital, Hangzhou
NOT_YET_RECRUITING
The second Affiliated Hospital of Kunming Medical University, Kunming
RECRUITING
The second Affiliated Hospital of Nanchang University, Nanchang
NOT_YET_RECRUITING
Jiangsu Province Hospital, Nanjing
RECRUITING
Shanghai Chest Hospital, Shanghai
RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
RECRUITING
Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Air Force Medical University of PLA (the Fourth Military Medical University), Xi'an
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
Henan Provincial People's Hospital, Zhengzhou
Collaborators (1)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
INDUSTRY
Fujian Cancer Hospital
OTHER_GOV